Compare SMHI & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMHI | NGEN |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 197.5M |
| IPO Year | 2016 | N/A |
| Metric | SMHI | NGEN |
|---|---|---|
| Price | $8.35 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 170.1K | ★ 833.4K |
| Earning Date | 04-29-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $173,783,000.00 | N/A |
| Revenue This Year | $1.21 | N/A |
| Revenue Next Year | $9.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $1.70 |
| 52 Week High | $8.47 | $5.93 |
| Indicator | SMHI | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 32.74 |
| Support Level | $6.89 | N/A |
| Resistance Level | N/A | $2.28 |
| Average True Range (ATR) | 0.48 | 0.14 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 88.73 | 0.93 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.